Title |
In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum
|
---|---|
Published in |
Malaria Journal, May 2014
|
DOI | 10.1186/1475-2875-13-189 |
Pubmed ID | |
Authors |
Jérome Dormoi, Hélène Savini, Rémy Amalvict, Eric Baret, Bruno Pradines |
Abstract |
There is an urgent need for the discovery of new anti-malarial drugs and combination therapy. A combinatorial approach protects each drug from the development of resistance and reduces generally the overall transmission rate of malaria. Statins, the inhibitors of 3-hydroxy-3-methylglutaryl-Coenzyme A reductase and a family of lipid-lowering drugs, have in vitro anti-malarial properties, and more specially atorvastatin. However, atorvastatin has a short elimination half-life (14 hours) and an efficient combination of anti-malarial drugs must associate a drug with a short elimination half-life and a drug with a long elimination half-life. The objective of the present work was to identify new potential partners among standard new anti-malarial drugs with long elimination half-life, such as lumefantrine, piperaquine, pyronaridine and atovaquone, to improve the in vitro activity of atorvastatin against different Plasmodium falciparum strains to treat uncomplicated malaria. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 6% |
Unknown | 15 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 3 | 19% |
Lecturer | 2 | 13% |
Student > Ph. D. Student | 2 | 13% |
Other | 1 | 6% |
Lecturer > Senior Lecturer | 1 | 6% |
Other | 3 | 19% |
Unknown | 4 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 3 | 19% |
Biochemistry, Genetics and Molecular Biology | 3 | 19% |
Medicine and Dentistry | 3 | 19% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 13% |
Immunology and Microbiology | 1 | 6% |
Other | 0 | 0% |
Unknown | 4 | 25% |